The RTEL1 rs6010620 Polymorphism and Glioma Risk: a Meta-analysis Based on 12 Case-control Studies

  • Du, Shu-Li (School of Life Sciences, Northwest University) ;
  • Geng, Ting-Ting (National Engineering Research Center for Miniaturized Detection Systems) ;
  • Feng, Tian (National Engineering Research Center for Miniaturized Detection Systems) ;
  • Chen, Cui-Ping (National Engineering Research Center for Miniaturized Detection Systems) ;
  • Jin, Tian-Bo (School of Life Sciences, Northwest University) ;
  • Chen, Chao (School of Life Sciences, Northwest University)
  • Published : 2015.01.06


Background: The association between the RTEL1 rs6010620 single nucleotide polymorphism (SNP) and glioma risk has been extensively studied. However, the results remain inconclusive. To further examine this association, we performed a meta-analysis. Materials and Methods: A computerized search of the PubMed and Embase databases for publications regarding the RTEL1 rs6010620 polymorphism and glioma cancer risk was performed. Genotype data were analyzed in a meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association. Sensitivity analyses, tests of heterogeneity, cumulative meta-analyses, and assessments of bias were performed in our meta-analysis. Results: Our meta-analysis confirmed that risk with allele A is lower than with allele G for glioma. The A allele of rs6010620 in RTEL1 decreased the risk of developing glioma in the 12 case-control studies for all genetic models: the allele model (OR=0.752, 95%CI: 0.715-0.792), the dominant model (OR=0.729, 95%CI: 0.685-0.776), the recessive model (OR=0.647, 95%CI: 0.569-0.734), the homozygote comparison (OR=0.528, 95%CI: 0.456-0.612), and the heterozygote comparison (OR=0.761, 95%CI: 0.713-0.812). Conclusions: In all genetic models, the association between the RTEL1 rs6010620 polymorphism and glioma risk was significant. This meta-analysis suggests that the RTEL1 rs6010620 polymorphism may be a risk factor for glioma. Further functional studies evaluating this polymorphism and glioma risk are warranted.


Meta-analysis;glioma;case-control studies;polymorphism;RTEL1 gene


  1. Adelman CA, Boulton SJ (2010). Metabolism of postsynaptic recombination intermediates. FEBS Lett, 584, 3709-16.
  2. Bai C, Connolly B, Metzker ML, et al (2000). Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a fourgene cluster. Proc Natl Acad Sci USA, 97, 1230-5.
  3. Barber LJ, Youds JL, Ward JD, et al (2008). RTEL1 maintains genomic stability by suppressing homologous recombination. Cell, 135, 261-71.
  4. Chen H, Sun B, Zhao Y, et al (2012). Fine mapping of a region of chromosome 11q23.3 reveals independent locus associated with risk of glioma. PLoS One, 7, 52864.
  5. Das BR, Tangri R, Ahmad F, et al (2013). Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients. Asian Pac J Cancer Prev, 14, 7261-4.
  6. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  7. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  8. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  9. Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.
  10. Jin TB, Zhang JY, Li G, et al (2013). RTEL1 and TERT polymorphisms are associated with astrocytoma risk in the Chinese Han population. Tumour Biol, 34, 3659-66.
  11. Li G, Jin TB, Liang HJ, et al (2013). RTEL1 tagging SNPs and haplotypes were associated with glioma development. Diagnostic Pathology, 8, 83.
  12. Liang HJ, Yan YL, Liu ZM, et al (2013). Association of XRCC3 Thr241Met polymorphisms and glioma risk: evidence from a meta-analysis. Asian Pac J Cancer Prev, 14, 4243-7.
  13. Little MP, de Vathaire F, Shamsaldin A, et al (1998). Risks of brain tumour following treatment for cancer in childhood: modification by genetic factors, radiotherapy and chemotherapy. Int J Cancer, 78, 269-75.<269::AID-IJC1>3.0.CO;2-T
  14. Liu Y, Shete S, Etzel CJ, et al (2010). Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the doublestrand break repair pathway predict glioblastoma survival. J Clin Oncol, 28, 2467-74.
  15. Liu Y, Zhang H, Zhou K, et al (2007). Tagging SNPs in nonhomologous end-joining pathway genes and risk of glioma. Carcinogenesis, 28, 1906-13.
  16. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  17. Mirabello L, Yu K, Kraft P, et al (2010). The association of telomere length and genetic variation in telomere biology genes. Hum Mutat, 31, 1050-8.
  18. Neglia JP, Robison LL, Stovall M, et al (2006). New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst, 98, 1528-37.
  19. Qin X, Peng Q, Tang W, et al (2013). An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk. PLoS One, 8, 76031.
  20. Schoemaker MJ, Robertson L, Wigertz A, et al (2010). Interaction between 5 genetic variants and allergy in glioma risk. Am J Epidemiol, 171, 1165-73.
  21. Shete S, Hosking FJ, Robertson LB, et al (2009). Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet, 41, 899-904.
  22. Uringa EJ, Lisaingo K, Pickett HA, et al (2012). RTEL1 contributes to DNA replication and repair and telomere maintenance. Mol Biol Cell, 23, 2782-92.
  23. Uringa EJ, Youds JL, Lisaingo K, et al (2011). RTEL1: an essential helicase for telomere maintenance and the regulation of homologous recombination. Nucleic Acids Res, 39, 1647-55.
  24. Walcott F, Rajaraman P, Gadalla SM, et al (2013). Telomere length and risk of glioma. Cancer Epidemiol, 37, 935-8.
  25. Walsh KM, Anderson E, Hansen HM, et al (2013a). Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. Genet Epidemiol, 37, 222-8.
  26. Walsh KM, Rice T, Decker PA, et al (2013b). Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. Neuro-Oncology, 15, 1041-7.
  27. Wrensch M, Jenkins RB, Chang JS, et al (2009). Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet, 41, 905-8.
  28. Youds JL, Mets DG, McIlwraith MJ, et al (2010). RTEL-1 enforces meiotic crossover interference and homeostasis. Science, 327, 1254-8.

Cited by

  1. Association of the CCDC26 rs4295627 polymorphism with the risk of glioma: Evidence from 7,290 cases and 11,630 controls vol.4, pp.5, 2016,
  2. Association between regulator of telomere elongation helicase1 (RTEL1) gene and HAPE risk vol.96, pp.39, 2017,
  3. ) and coronary heart disease risk pp.23249269, 2019,